UCB gets access to rights for an antibody programme from WILEX for non-oncology indications
WILEX AG and UCB announced that UCB has acquired an antibody programme from WILEX’ preclinical portfolio originally obtained from UCB in 2009. UCB has the right to develop the antibodies from the programme in any indication outside the field of oncology, while WILEX keeps the rights to develop for oncology indications.
WILEX will be reimbursed an undisclosed amount for its development costs to date and shall be eligible for future, undisclosed development, regulatory and commercial milestone payments as well as royalties.
UCB and WILEX will continue to share data regarding the programme through the existing development committee structures. UCB will be working on these antibodies in immunology/inflammation and, as part of the strategic partnership between the two companies, will make available to WILEX the relevant data to assist WILEX in oncology.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Reactive_arthritis
AFFiRiS AG: Alzheimer's Vaccine Candidate AD02 moves into Clinical Phase II Testing
Ehrfeld Mikrotechnik BTS and Lonza cooperate in the microreactor technology
DeCODE Initiates Phase III Trial for DG031 for the Prevention of Heart Attack - Pioneering use of human genetics to target the causative biology
